There’s some news on the Type 2 Diabetes front. A recent report from a study conducted on 278 patients at 56 medical centers in the United States and six other countries found that rimonabant (brand name Acomplia), helped improve blood sugar control while also promoting weight loss in patients with type 2 diabetes. It is important to note that the drug maker Sanofi-Aventis released these study results.
Another promising find is the drug seems to have a positive effect on good and bad cholesterol, blood pressure and triglycerides – other risk factors for developing Type 2. This is the second study to find that rimonabant improves blood sugar levels in people with type 2 diabetes. The previous study, funded by Sanofi-Aventis, was published online Oct. 27 in the journal The Lancet.
Rimonabant is approved in Europe but has not been approved in the United States.